FIELD: chemistry.
SUBSTANCE: invention relates to a compound of formula (I) or pharmaceutically acceptable salts thereof, where 
denotes a double or single bond, G1, G2 and G3 are identical or different, each independently selected from a group consisting of C, CH, CH2 and N, Ring A is selected from a group consisting of phenyl, pyridyl, imidazolyl, pyrazolyl and morpholinyl, each of R1 is identical or different, wherein each is independently selected from a group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, cyano, amino, nitro, hydroxy and C1-6 hydroxyalkyl, R2 is C1-6 haloalkyl, R3 is selected from a group consisting of C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 hydroxyalkyl, halogen and hydroxy, each of R4 is identical or different, each being independently selected from a group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, cyano, amino, nitro, hydroxy and C1-6 hydroxyalkyl, R5 is selected from a group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, amino, hydroxy, C1-6 hydroxyalkyl, 3−6-member cycloalkyl and NR10R11, where each of C1-6 alkyl and 3−6-member cycloalkyl is independently optionally substituted with one or more substitutes selected from a group consisting of hydroxy, halogen, C1-6 alkyl, amino, 3−6-member cycloalkyl and 3−6-member heterocyclyl, each of R6 is identical or different, each being independently selected from a group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, cyano, amino, nitro, hydroxy and C1-6 hydroxyalkyl, R7 is selected from a group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl and 3−6-member cycloalkyl, where C1-6 alkyl is optionally substituted with one or more substitutes selected from a group consisting of halogen, nitro and 3−6-member cycloalkyl, R8 and R9 are identical or different, each being independently selected from a group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, cyano, amino, nitro, hydroxy and C1-6 hydroxyalkyl, R10 and R11 are identical or different, each being independently selected from a group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, amino, hydroxy, C1-6 hydroxyalkyl and 3−6-member cycloalkyl , n equals 0 or 1, s equals 0 or 1, and t equals 0 or 1.
EFFECT: technical result is obtaining novel compounds of formula (I), which can be used in medicine for treating tumor diseases mediated by RORγ.
13 cl, 2 tbl, 1 dwg, 17 ex
